ALISO VIEJO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three and six months ended June 30, 2023.
Key Quarterly Highlights
“This quarter’s performance marks our 10th consecutive period of solid, year-over-year quarterly revenue growth, reflecting the increasing number of doctors and patients who are selecting our novel LAL system for the precise, high-quality visual outcomes it provides,” said Ron Kurtz, Chief Executive Officer and President of RxSight. “The LAL is the first and only lens that can be customized after cataract surgery, providing patients the opportunity to preview and adjust their vision to meet their specific needs and preferences. While the LAL is still in the early adoption phase, we believe it can ultimately occupy a leading position in the premium cataract market.”
Second Quarter Financial Results
In the second quarter of 2023, total revenue was $20.8 million, an increase of 83% compared to $11.4 million in the second quarter of 2022. Revenue growth was driven by a 36% increase in LDD revenue and a 132% increase in LAL revenue compared to the second quarter of 2022.
Gross profit for the second quarter of 2023 was $12.0 million or 58% of revenue, an increase of $7.2 million or 151% compared to gross profit of $4.8 million or 42% of revenue for the second quarter of 2022.
Total operating expenses for the second quarter of 2023 were $25.6 million, a 25% increase from $20.6 million in the second quarter of 2022, reflecting the company’s ongoing investments to grow its LDD installed base and support increased LAL procedure volumes.
In the second quarter of 2023, the company reported a net loss of $(13.8) million, or $(0.40) per basic and diluted share, compared to net loss of $(16.7) million, or $(0.61) per basic and diluted share in the second quarter of 2022. Adjusted net loss in the second quarter of 2023 was $(9.5) million, or $(0.28) per basic and diluted share, compared to an adjusted net loss of $(13.8) million, or $(0.50) per basic and diluted share in the second quarter of 2022.
Cash, cash equivalents and short-term investments as of June 30, 2023, were $147.1 million compared to $153.9 million at March 31, 2023. In the second quarter of 2023, the company raised approximately $19.4 million, net after fees, through the sale of common stock under its “at-the-market” (“ATM”) facility. During the second quarter of 2023, the company used these proceeds and cash reserves to reduce its outstanding debt by $20.0 million and pay associated accrued interest and fees.
Early in the third quarter of 2023, the company raised additional proceeds of approximately $11.9 million, net of fees, through the sale of common stock under its ATM facility. The company used these proceeds and cash reserves to pay off its remaining $20.0 million term loan balance as well as associated accrued interest and fees. Through the elimination of $40.0 million in debt in the second and third quarters of 2023, the company expects to reduce its annual interest expense by approximately $5.6 million.
Financial Outlook
Based on second quarter 2023 performance, the company increased its 2023 full-year revenue, gross margin and operating expense guidance as follows:
Conference Call
On Monday, August 7, 2023, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its second quarter 2023 financial results. Participants may register for the call here and listen through a live and archived webcast of the event available for one year at https://investors.rxsight.com/. While not required, it is recommended participants join ten minutes prior to the event start time to ensure the necessary audio applications are downloaded and installed. Instructions are provided (including a dial-in option).
About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery enabling doctors to customize and deliver high-quality of vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Forward-Looking Statements
This press release contains forward-looking statements, including with respect to the Company’s revenue growth trends; the increasing number of doctors and patients who are selecting the Company’s novel LAL; the ability of the Company’s LAL to occupy a leading position in the premium cataract market; and the Company’s projected revenue, gross margin, and operating expenses for 2023. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Company Contact:
Shelley B. Thunen
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
RxSIGHT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS (UNAUDITED)
(In thousands, except share and per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||
| Sales | $ | 20,810 | $ | 11,360 | $ | 38,299 | $ | 20,301 | |||||||||
| Cost of sales | 8,795 | 6,572 | 15,919 | 11,752 | |||||||||||||
| Gross profit | 12,015 | 4,788 | 22,380 | 8,549 | |||||||||||||
| Operating expenses: | |||||||||||||||||
| Selling, general and administrative | 18,239 | 14,388 | 34,492 | 28,008 | |||||||||||||
| Research and development | 7,401 | 6,192 | 14,608 | 12,911 | |||||||||||||
| Total operating expenses | 25,640 | 20,580 | 49,100 | 40,919 | |||||||||||||
| Loss from operations | (13,625 | ) | (15,792 | ) | (26,720 | ) | (32,370 | ) | |||||||||
| Other income (expense), net: | |||||||||||||||||
| Interest expense | (1,568 | ) | (1,136 | ) | (3,075 | ) | (2,196 | ) | |||||||||
| Interest and other income | 1,777 | 196 | 3,168 | 242 | |||||||||||||
| Loss on extinguishment of term loan | (362 | ) | — | (362 | ) | — | |||||||||||
| Loss before income taxes | (13,778 | ) | (16,732 | ) | (26,989 | ) | (34,324 | ) | |||||||||
| Income tax expense | 26 | — | 27 | 4 | |||||||||||||
| Net loss | $ | (13,804 | ) | $ | (16,732 | ) | $ | (27,016 | ) | $ | (34,328 | ) | |||||
| Other comprehensive income (loss) | |||||||||||||||||
| Unrealized (loss) gain on short-term investments | (65 | ) | (76 | ) | 19 | (150 | ) | ||||||||||
| Foreign currency translation gain (loss) | 1 | (9 | ) | 3 | (13 | ) | |||||||||||
| Total other comprehensive (loss) income | (64 | ) | (85 | ) | 22 | (163 | ) | ||||||||||
| Comprehensive loss | $ | (13,868 | ) | $ | (16,817 | ) | $ | (26,994 | ) | $ | (34,491 | ) | |||||
| Net loss per share: | |||||||||||||||||
| Basic & diluted | $ | (0.40 | ) | $ | (0.61 | ) | $ | (0.82 | ) | $ | (1.25 | ) | |||||
| Weighted-average shares used in computing net loss per share: | |||||||||||||||||
| Attributable to common stock, basic & diluted | 34,498,265 | 27,559,908 | 33,075,585 | 27,493,130 | |||||||||||||
RxSIGHT, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands, except share and per share amounts)
| June 30, | December 31, | |||||||
| 2023 | 2022 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 8,753 | $ | 11,834 | ||||
| Short-term investments | 138,340 | 93,968 | ||||||
| Accounts receivable | 13,295 | 10,956 | ||||||
| Inventories | 17,945 | 14,835 | ||||||
| Prepaid and other current assets | 2,112 | 2,962 | ||||||
| Total current assets | 180,445 | 134,555 | ||||||
| Property and equipment, net | 10,533 | 10,138 | ||||||
| Operating leases right-of-use assets | 3,174 | 3,943 | ||||||
| Restricted cash | 761 | 761 | ||||||
| Other assets | 348 | 767 | ||||||
| Total assets | $ | 195,261 | $ | 150,164 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,997 | $ | 2,595 | ||||
| Accrued expenses and other current liabilities | 10,588 | 12,672 | ||||||
| Lease liabilities | 1,980 | 1,970 | ||||||
| Total current liabilities | 16,565 | 17,237 | ||||||
| Long-term lease liabilities | 1,843 | 2,856 | ||||||
| Term loan, net | 19,589 | 40,169 | ||||||
| Other long-term liabilities | 76 | — | ||||||
| Total liabilities | 38,073 | 60,262 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Common stock, $0.001 par value, 900,000,000 shares authorized, 35,168,041 shares issued and outstanding as of June 30, 2023 and 28,268,389 shares issued and outstanding as of December 31, 2022 | 35 | 28 | ||||||
| Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding | — | — | ||||||
| Additional paid-in capital | 730,274 | 636,001 | ||||||
| Accumulated other comprehensive loss | (73 | ) | (95 | ) | ||||
| Accumulated deficit | (573,048 | ) | (546,032 | ) | ||||
| Total stockholders' equity | 157,188 | 89,902 | ||||||
| Total liabilities and stockholders' equity | $ | 195,261 | $ | 150,164 | ||||
Non-GAAP Financial Measures
To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States (“GAAP”), we believe certain non-GAAP measures, including adjusted net loss, and adjusted net loss per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense and loss on extinguishment of debt because these expenses are non-cash in nature and we believe excluding these items provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies.
We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.
Adjusted Net Loss and Adjusted Net Loss Per Share
Adjusted net loss is a non-GAAP financial measure that we define as net loss adjusted for (i) stock-based compensation and (ii) loss on extinguishment of term loan. We believe adjusted net loss provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.
Reconciliations of net loss to adjusted net loss and the presentation of adjusted net loss per share, basic and diluted, are as follows:
RxSIGHT, INC.
GAAP To NON-GAAP RECONCILIATIONS (UNAUDITED)
(In thousands, except share and per share amounts)
| Three months ended June 30, | Six months ended June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Common Stock | ||||||||||||||||
| Numerator: | ||||||||||||||||
| Net loss available to stockholders, basic and diluted | $ | (13,804 | ) | $ | (16,732 | ) | $ | (27,016 | ) | $ | (34,328 | ) | ||||
| Add: | ||||||||||||||||
| Stock-based compensation | 3,955 | 2,904 | 7,250 | 5,553 | ||||||||||||
| Loss on extinguishment of term loan | 362 | — | 362 | — | ||||||||||||
| Adjusted net loss available to common stockholders, basic and diluted: | $ | (9,487 | ) | $ | (13,828 | ) | $ | (19,404 | ) | $ | (28,775 | ) | ||||
| Denominator: | ||||||||||||||||
| Weighted-average shares outstanding, basic and diluted | 34,498,265 | 27,559,908 | 33,075,585 | 27,493,130 | ||||||||||||
| Adjusted net loss per share, basic and diluted | $ | (0.28 | ) | $ | (0.50 | ) | $ | (0.59 | ) | $ | (1.05 | ) | ||||
| Last Trade: | US$43.72 |
| Daily Change: | -2.12 -4.62 |
| Daily Volume: | 153,392 |
| Market Cap: | US$1.760B |
November 07, 2024 August 05, 2024 May 06, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
